Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
BLLN vs GH: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
BLLN Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 7–3 Matrix Metrics)
BLLN Overall Winner
6-Pillar Tally: BLLN 6 – 0 GH
Matrix Metrics: BLLN 7 – 3 GH
As of Nov 16, 2026, BillionToOne, Inc. (BLLN) is the stronger overall head-to-head candidate over Guardant Health, Inc. (GH) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BLLN carries a Unified Composite Score of 45.8/100 (HOLD) at $96.31 (61.3x Forward P/E, 10.2% operating margin), whereas GH carries 48.4/100 (HOLD) at $144.03 (N/M Forward P/E, -39.4% operating margin).
- Composite vs. Pillar Nuance: While GH currently prints a higher short-term Unified Composite Score (48.4/100 HOLD vs. BLLN 45.8/100 HOLD), BLLN captures the overall institutional head-to-head verdict (7–3 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (10.2% vs. -39.4% operating margin) and revenue trajectory (+47.2% vs. +36.1% YoY).
- Technical & Structure Timing Caution: BLLN is currently in a Breakdown options structure phase (RSI 34.4); meanwhile GH trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 34.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About BLLN vs GH
BLLN
Head-to-Head Winner
BillionToOne, Inc.
$96.31
-8.41% 1D
Market Cap
$5.0B
TTM Revenue
$437M
Forward P/E
61.3x
Beta / 30D Vol
1.44β · 42% Vol
Unified Composite Score
45.8
HOLD
Tech 27.0
Fund 53.0
Flow 71.0
Mom 70.0
Weinstein Technical Phase
Neutral · Hold
GH
Guardant Health, Inc. Common Stock
$144.03
-5.06% 1D
Market Cap
$20.5B
TTM Revenue
$1.28B
Forward P/E
N/M
Beta / 30D Vol
1.32β · 56% Vol
Unified Composite Score
48.4
HOLD
Tech 19.0
Fund 48.0
Flow 67.0
Mom 64.0
Weinstein Technical Phase
Neutral · Hold
6-Pillar Scorecard Institutional Category Breakdown (BLLN 6 – 0 GH)
1. Valuation Multiples
BLLN
Forward P/E
61.3x
N/M
Trailing P/E
114.3x
N/M
PEG Ratio
N/M
N/M
EV / Revenue
10.5x
16.6x
2. Growth & Scale
BLLN
Revenue Growth (YoY)
+47.2%
+36.1%
Earnings Growth (YoY)
+220.0%
+0.0%
TTM Revenue (USD)
$437M
$1.28B
Market Cap
$5.0B
$20.5B
3. Profitability & Quality
BLLN
Gross Margin
71.4%
65.2%
Operating Margin
10.2%
-39.4%
Net Profit Margin
10.5%
-37.9%
Return on Equity (ROE)
13.2%
0.0%
4. Balance Sheet & Cash Flow
BLLN
Cash Generation (TTM)
$34M
-$232M
Cash Flow Margin
7.8%
-18.2%
Net Cash / Leverage
$421M Net Cash
$665M Net Debt
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
BLLN
Options Structure Phase
BREAKDOWN
CONSOLIDATION
Current IV / %ile
113.8% (26th %ile)
72.2% (31st %ile)
Put/Call OI Skew
1.21x (Put-Skewed)
3.50x (Put-Skewed)
OBV Trend / Tech Phase
DISTRIBUTION · Neutral
DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat
BLLN
OpEx & R&D Intensity
61.2% of Rev ($267M)
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Diagnostics & Research Operator
Diagnostics & Research Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: BLLN (7) vs GH (3)| Institutional Metric | BLLN | GH | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $5.0B | $20.5B | GH | |
| Trailing P/E Ratio | 114.3x | N/M | BLLN | |
| Forward P/E Ratio | 61.3x | N/M | BLLN | |
| Revenue Growth (YoY) | +47.2% | +36.1% | BLLN | |
| Operating Margin (TTM) | 10.2% | -39.4% | BLLN | |
| Net Profit Margin | 10.5% | -37.9% | BLLN | |
| Return on Equity (ROE) | 13.2% | 0.0% | BLLN | |
| 52-Week Range Position | 39% ($62–$150) | 60% ($75–$191) | GH | |
| Beta / 30D Volatility | 1.44β · 42% Vol | 1.32β · 56% Vol | BLLN | |
| Unified Institutional Score | 45.8 / 100 (HOLD) | 48.4 / 100 (HOLD) | GH | |
| Trailing 12M Revenue (USD) | $437M | $1.28B | Scale | |
| Gross Profit Margin (TTM) | 71.4% | 65.2% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 10.5x EV/Rev | N/M PEG · 16.6x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | $34M ($421M Net Cash) | -$232M ($665M Net Debt) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
BLLN +7.35 pp
3M Horizon
BLLN +19.51 pp
6M Horizon
GH +38.73 pp
1Y Horizon
GH +45.46 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | BLLN Revenue | GH Revenue | BLLN Op. Margin | GH Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | N/A | $90M | N/A | -102.5% | GH |
| FY2019 | N/A | $210M | N/A | -38.4% | GH |
| FY2020 | N/A | $290M | N/A | -88.9% | GH |
| FY2021 | N/A | $370M | N/A | -110.0% | GH |
| FY2022 | N/A | $450M | N/A | -121.1% | GH |
| FY2023 | $70M | $560M | -96.9% | -100.1% | BLLN |
| FY2024 | $150M | $740M | -30.9% | -60.0% | BLLN |
| FY2025 | $310M | $980M | 5.3% | -44.5% | BLLN |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
BLLN
BREAKDOWN
Current IV
113.8%
IV Percentile
26th %ile
Put/Call OI Skew
1.21x (Put-Skewed)
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
DISTRIBUTION
Exact BLLN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
GH
CONSOLIDATION
Current IV
72.2%
IV Percentile
31st %ile
Put/Call OI Skew
3.50x (Put-Skewed)
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BEARISH
OBV Flow
DISTRIBUTION
Exact GH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
BLLN Moat Profile
Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
OpEx & R&D Reinvestment
61.2% of Rev ($267M)
90D Engineering Disclosures
0 Published
GH Moat Profile
Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ BLLN vs GH Key Questions & Quantitative Answers
As of Nov 16, 2026, BillionToOne, Inc. (BLLN) is the stronger overall head-to-head candidate over Guardant Health, Inc. (GH) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BLLN carries a Unified Composite Score of 45.8/100 (HOLD) at $96.31 (61.3x Forward P/E, 10.2% operating margin), whereas GH carries 48.4/100 (HOLD) at $144.03 (N/M Forward P/E, -39.4% operating margin). Composite vs. Pillar Nuance: While GH currently prints a higher short-term Unified Composite Score (48.4/100 HOLD vs. BLLN 45.8/100 HOLD), BLLN captures the overall institutional head-to-head verdict (7–3 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (10.2% vs. -39.4% operating margin) and revenue trajectory (+47.2% vs. +36.1% YoY). Technical & Structure Timing Caution: BLLN is currently in a Breakdown options structure phase (RSI 34.4); meanwhile GH trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 34.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
BLLN leads the Growth & Scale pillar: BLLN posts +47.2% YoY revenue growth and +220.0% YoY earnings growth on $437M TTM revenue (71.4% gross margin, 10.2% operating margin), compared with GH at +36.1% YoY revenue growth and +0.0% YoY earnings growth on $1.28B TTM revenue (65.2% gross margin, -39.4% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), BLLN cumulative revenue shifted +342.9% while GH shifted +988.9%. In operating R&D and SG&A reinvestment, BLLN deploys 61.2% of Rev ($267M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for GH.
BLLN screens cheaper on headline valuation multiples. BLLN trades at 61.3x Forward P/E, 114.3x Trailing P/E, N/M PEG, and 10.5x EV/Revenue (7.8% FCF margin), whereas GH trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 16.6x EV/Revenue (-18.2% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BLLN (13.2% ROE) versus GH (0.0% ROE) capital efficiency.
In options market volatility and institutional positioning, BLLN carries 113.8% implied volatility (26th %ile, Balanced (25th–60th %ile)), a 1.21x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.44β · 42% Vol realized risk). By comparison, GH carries 72.2% implied volatility (31st %ile, Balanced (25th–60th %ile)), a 3.50x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.32β · 56% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
GH vs BLLN · Reverse Pair
BLLN vs HNGE
· Sector Peer
BLLN vs MDLN
· Sector Peer
BLLN vs FPS
· Sector Peer
GH vs NTRA
· Sector Peer
GH vs TXG
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem